Everything below concerns Heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-03. Numbers and descriptions here follow the published literature rather than marketing material.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Lyophilised storage | −20 °C, dry, protected from light | Vials are sealed and allowed to reach room temperature before opening |
| Reconstituted storage | 2 to 8 °C, protected from light | Short-term holding; avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Water for injection or bacteriostatic water | Added slowly along the vial wall to reduce foaming and shear |
| Purity measurement | RP-HPLC with area normalisation | Acetonitrile-water gradient monitored at roughly 214 nm |
| Identity confirmation | Electrospray ionisation mass spectrometry | Observed mass compared against the calculated peptide mass |
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
=== Beginning === Most early progress in tissue engineering research was done in the US. This is due to less strict regulations regarding stem cell research and more available funding than in other countries. This leads to the creation of academic startups many of them coming from Harvard or MIT. Examples are BioHybrid Technologies whose founder, Bill Chick, went to Harvard Medical School and focused on the creation of artificial pancreas. Another example would be Organogenesis Inc. whose founder went to MIT and worked on skin engineering products. Other companies with links to the MIT are TEI Biosciences, Therics and Guilford Pharmaceuticals. The renewed interest in biotechnologies in the 1980s leads to many private investors investing in these new technologies even though the business models of these early startups were often not very clear and did not present a path to long term profitability. Government sponsors were more restrained in their funding as tissue engineering was considered a high-risk investment. In the UK the market got off to a slower start even though the regulations on stem cell research were not strict as well. This is mainly due to more investors being less willing to invest in these new technologies which were considered to be high-risk investments. Another problem faced by British companies was getting the NHS to pay for their products. This especially because the NHS runs a cost-effectiveness analysis on all supported products. Novel technologies often do not do well in this respect. In Japan, the regulatory situation was quite different.
=== Main === Erika Toda as Kazuko Hosoki, a woman who rises from poverty in postwar Japan to become a Ginza club owner and later a nationally famous fortune teller. Sairi Ito as Minori Uozumi, a young novelist and single mother hired to write a book about Kazuko's life.
While the main habitat of earthworms is in soil, they are not restricted to this habitat. The brandling worm Eisenia fetida lives in decaying plant matter and manure. Arctiostrotus vancouverensis from Vancouver Island and the Olympic Peninsula is generally found in decaying conifer logs. Aporrectodea limicola, Sparganophilus spp., and several others are found in mud in streams (riparian species). Some species are arboreal, some aquatic and some euryhaline (salt-water tolerant) and littoral (living on the sea-shore), e.g. Pontodrilus litoralis. Even in the soil species, special habitats, such as ultramafic soils derived from serpentine, have an earthworm fauna of their own, e.g. New Caledonian Acanthodrilidae. Vermicomposting of organic wastes is currently processed using the epigeic Eisenia fetida and Eisenia andrei which are particularly adapted to the consumption of fresh organic matter without deepening in the substrate (contrary to the anecis Lumbricus terrestris) and which tolerate the heat generated in compost heaps. Addition of this humified organic matter to the soil, preferably as a surface mulch, will improve moisture and nutrient availability, with beneficial effects on the soil microflora. It will also provide several species of earthworms with their food and nutrient requirements, and will create the optimum conditions of temperature and moisture that will stimulate their activity, although to a lesser extent than bacterial-mediated compost. Earthworms are environmental indicators of soil health.
The underlying principle of COLD-PCR is that single nucleotide mismatches will slightly alter the melting temperature (Tm) of the double-stranded DNA. Depending on the sequence context and position of the mismatch, Tm changes of 0.2–1.5 °C (0.36–2.7 °F) are common for sequences up to 200bp or higher. Knowing this the authors of the protocol took advantage of two observations:
Water fit for human consumption is called drinking water or potable water. Water that is not potable may be made potable by filtration or distillation, or by a range of other methods. More than 660 million people do not have access to safe drinking water. Water that is not fit for drinking but is not harmful to humans when used for swimming or bathing is called by various names other than potable or drinking water, and is sometimes called safe water, or "safe for bathing". Chlorine is a skin and mucous membrane irritant that is used to make water safe for bathing or drinking. Its use is highly technical and is usually monitored by government regulations (typically 1 part per million (ppm) for drinking water, and 1–2 ppm of chlorine not yet reacted with impurities for bathing water). Water for bathing may be maintained in satisfactory microbiological condition using chemical disinfectants such as chlorine or ozone or by the use of ultraviolet light. Water reclamation is the process of converting wastewater (most commonly sewage, also called municipal wastewater) into water that can be reused for other purposes. There are 2.3 billion people who reside in nations with water scarcities, which means that each individual receives less than 1,700 cubic metres (60,000 cu ft) of water annually. 380 billion cubic metres (13×10^12 cu ft) of municipal wastewater are produced globally each year.
Sources: en.wikipedia.org
== 1965–68 == In 1965, SANROC was banned by the South African government, and Dennis Brutus re-established it in exile in London. In 1966, the Organisation of African Unity established the Supreme Council for Sport in Africa (SCSA), which committed itself to expelling South Africa from the Olympics and to boycott the Games if South Africa was present. The Association of National Olympic Committees of Africa (ANOCA) allowed SANROC to affiliate in place of SANOC. (Brundage later made SANROC change "Olympic" to "Open" in its name.) At the 1967 IOC conference in Tehran, SANOC committed to sending a single mixed-race team to the 1968 Summer Olympics in Mexico City. Separate racial committees would nominate athletes for each race to the combined team. Members from different races could compete against each other at the Games, though not in South Africa. The IOC deferred decision till its meeting at the 1968 Winter Olympics in Grenoble. In September 1967, a three-member IOC commission visited South Africa, reporting back in January 1968. It was led by Lord Killanin, a future IOC president, who resigned from the Irish Anti-Apartheid Society to forestall allegations of bias; the other members were Ade Ademola, a black Nigerian, and Reginald Alexander, a white Kenyan. Killanin later recalled that Ademola was repeatedly snubbed in South Africa, and that of whites they interviewed, athletes favoured integrated competition, administrators less so, and politicians Frank Waring and John Vorster not at all.
A few examples of character strength according to Character Strength and Virtues: A Handbook and Classification by Seligman and Peterson (2004) are bravery, integrity, citizenship, humility, prudence, gratitude, and hope, all of which are shown in the rise to recovery. Thirdly, the Meaningful Life is service and membership to positive organizations. Examples of positive organizations include family, workplace, social groups, and society in general. Membership of these groups fosters positive affect, while also promoting character strengths, which as seen in the Engaged Life, can aid in beating addiction.
=== Synthesis === Cyanuric acid (CYA) was first synthesized by Friedrich Wöhler in 1829 by the thermal decomposition of urea and uric acid. The current industrial route to CYA entails the thermal decomposition of urea, with release of ammonia. The conversion commences at approximately 175 °C (347 °F):
DNA sequencing research, using microfluidics, also has the ability to be applied to the sequencing of RNA, using similar droplet microfluidic techniques, such as the method, inDrops. This shows that many of these DNA sequencing techniques will be able to be applied further and be used to understand more about genomes and transcriptomes.
== Strong bases == A strong base is a base that is quantitatively protonated upon exposure to water. This complete protonation is a result of the leveling effect. The term "strong base" can lead to confusion, since in this case "strong" is a category of base rather than a qualitative description. For example, guanidine is a very basic molecule, but it does not meet the definition of a strong base because it is not fully protonated by water. Common examples of strong bases include hydroxides of alkali metals and alkaline earth metals, like sodium hydroxide and calcium hydroxide, respectively. Due to their low solubility, some bases, such as alkaline earth hydroxides, can be used when the solubility factor is not taken into account. One advantage of this low solubility is that "many antacids were suspensions of metal hydroxides such as aluminium hydroxide and magnesium hydroxide"; compounds with low solubility and the ability to stop an increase in the concentration of the hydroxide ion, preventing the harm of the tissues in the mouth, oesophagus, and stomach. As the reaction continues and the salts dissolve, the stomach acid reacts with the hydroxide produced by the suspensions. Strong bases hydrolyze in water completely due to the leveling effect. In this process, the water molecule acts as an acid to protonate the base, resulting in the formation of a hydroxide anion. Under anhydrous conditions, some strong bases can even deprotonate weakly acidic C–H bonds. Here is a list of several strong bases:
Sources: en.wikipedia.org
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.
Liquid chromatography coupled to mass spectrometry is the most common approach because it combines a retention time with a mass measurement. A chromatographic peak alone cannot establish which peptide is present, so mass determination or amino acid analysis is used as an orthogonal confirmation alongside the separation.
This depends on buffer, pH, and concentration, and published stability data for this peptide are limited. In practice laboratories work through a refrigerated solution within a few weeks and discard samples that show cloudiness or visible particles. Freezing and thawing repeatedly is generally discouraged.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.